Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 809

Similar articles for PubMed (Select 15193680)

3.

Changes in left ventricular mass and volumes in patients receiving angiotensin-converting enzyme inhibitor therapy for left ventricular dysfunction after Q-wave myocardial infarction.

Foster RE, Johnson DB, Barilla F, Blackwell GG, Orr R, Roney M, Stanley AW Jr, Pohost GM, Dell'Italia LJ.

Am Heart J. 1998 Aug;136(2):269-75.

PMID:
9704689
4.

Angiotensin-converting enzyme inhibitor therapy affects left ventricular mass in patients with ejection fraction > 40% after acute myocardial infarction.

Johnson DB, Foster RE, Barilla F, Blackwell GG, Roney M, Stanley AW Jr, Kirk K, Orr RA, van der Geest RJ, Reiber JH, Dell'Italia LJ.

J Am Coll Cardiol. 1997 Jan;29(1):49-54.

5.

Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial.

Pfeffer MA, Greaves SC, Arnold JM, Glynn RJ, LaMotte FS, Lee RT, Menapace FJ Jr, Rapaport E, Ridker PM, Rouleau JL, Solomon SD, Hennekens CH.

Circulation. 1997 Jun 17;95(12):2643-51.

6.

Regional wall stress predicts ventricular remodeling after anteroseptal myocardial infarction in the Healing and Early Afterload Reducing Trial (HEART): an echocardiography-based structural analysis.

Aikawa Y, Rohde L, Plehn J, Greaves SC, Menapace F, Arnold MO, Rouleau JL, Pfeffer MA, Lee RT, Solomon SD.

Am Heart J. 2001 Feb;141(2):234-42.

PMID:
11174337
7.

Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial.

Colucci WS, Kolias TJ, Adams KF, Armstrong WF, Ghali JK, Gottlieb SS, Greenberg B, Klibaner MI, Kukin ML, Sugg JE; REVERT Study Group.

Circulation. 2007 Jul 3;116(1):49-56. Epub 2007 Jun 18.

8.

Effects of acute angiotensin-converting enzyme inhibition on diastolic ventricular interaction in the dilated heart.

Pepi M, Tamborini G, Maltagliati A, Guazzi M, Berna G, Susini F, Muratori M, Celeste F.

Clin Cardiol. 2003 Sep;26(9):424-30.

PMID:
14524600
9.

Treatment with ramipril improves systolic function even in patients with mild systolic dysfunction and symptoms of heart failure after acute myocardial infarction.

Kongstad-Rasmussen O, Blomstrand P, Broqvist M, Dahlström U, Wranne B.

Clin Cardiol. 1998 Nov;21(11):807-11.

PMID:
9825192
11.

Antihypertensive monotherapy with nisoldipine CC is superior to enalapril in black patients with severe hypertension.

Radevski I, Skudicky D, Candy G, Sathekge S, Strugo V, Sareli P.

Am J Hypertens. 1999 Feb;12(2 Pt 1):194-203.

PMID:
10090348
12.

The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction.

Yip GW, Wang M, Wang T, Chan S, Fung JW, Yeung L, Yip T, Lau ST, Lau CP, Tang MO, Yu CM, Sanderson JE.

Heart. 2008 May;94(5):573-80. doi: 10.1136/hrt.2007.117978. Epub 2008 Jan 20.

PMID:
18208835
13.

An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.

Miranda RD, Mion D Jr, Rocha JC, Kohlmann O Jr, Gomes MA, Saraiva JF, Amodeo C, Filho BL.

Clin Ther. 2008 Sep;30(9):1618-28. doi: 10.1016/j.clinthera.2008.09.008.

PMID:
18840367
14.

Effect of long-term therapy with ramipril in high-risk women.

Lonn E, Roccaforte R, Yi Q, Dagenais G, Sleight P, Bosch J, Suhan P, Micks M, Probstfield J, Bernstein V, Yusuf S; HOPE Investigators. Heart Outcomes Prevention Evaluation.

J Am Coll Cardiol. 2002 Aug 21;40(4):693-702.

15.

[Effects of ramipril and spironolactone on ventricular remodeling after acute myocardial infarction: randomized and double-blind study].

Rodríguez JA, Godoy I, Castro P, Quintana JC, Chávez E, Yovanovich J, Corbalán R, Chávez A.

Rev Med Chil. 1997 Jun;125(6):643-52. Spanish.

PMID:
9515282
16.

Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function.

Bertrand ME, Remme WJ, Fox KM, Ferrari R, Simoons ML; EUROPA investigators.

Int J Cardiol. 2007 Sep 14;121(1):57-61. Epub 2007 Jan 31.

PMID:
17270296
17.

Effect of dual blockade of renin-angiotensin system on TGFbeta1 and left ventricular structure and function in hypertensive patients.

Scaglione R, Argano C, Di Chiara T, Parrinello G, Colomba D, Avellone G, Donatelli M, Corrao S, Licata G.

J Hum Hypertens. 2007 Apr;21(4):307-15. Epub 2007 Feb 15.

PMID:
17301824
18.

Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy.

Roman MJ, Alderman MH, Pickering TG, Pini R, Keating JO, Sealey JE, Devereux RB.

Am J Hypertens. 1998 Apr;11(4 Pt 1):387-96.

PMID:
9607375
19.

Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril.

Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, Bosch J, Sussex B, Probstfield J, Yusuf S; Heart Outcomes Prevention Evaluation (HOPE) Investigators.

Circulation. 2001 Oct 2;104(14):1615-21.

20.

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.

Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G.

N Engl J Med. 2000 Jan 20;342(3):145-53. Erratum in: 2000 May 4;342(18):1376. N Engl J Med 2000 Mar 9;342(10):748.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk